clindamycin phosphate vaginal gel (DARE-BV1) / MilanaPharm, Hammock Pharma, Daré Biosci - LARVOL DELTA

Acceptability of Single-Dose Clindamycin Gel for Bacterial Vaginosis: A Randomized Controlled Trial. (PubMed, Clin Ther) - P3 | "A single dose of a new bioadhesive 2% clindamycin vaginal gel showed rapid resolution of symptoms and was highly acceptable as a treatment for bacterial vaginosis."

Journal • Vaginitis

Daré Bioscience (BIO 2022) - "The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. Daré’s product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application."

Sexual Disorders • Vaginitis • Women's Health

Pharmacokinetic Study of DARE-BV1 (clinicaltrials.gov) - P1 | N=21 | Completed | Sponsor: Daré Bioscience, Inc.

New P1 trial • Vaginitis

"CONGRATULATIONS on DARE-BV1 today. Pay up @Bayer #PDUFA $DARE https://t.co/57h4RnaKFu" (@MagplaneTechno1)

PDUFA date

[VIRTUAL] Daré Bioscience (BIO 2021) - "The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility. Daré’s product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a hormone-free, monthly contraceptive intravaginal ring whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and additional Phase 1 and preclinical candidates."

Sexual Disorders • Vaginitis • Women's Health

DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE) (clinicaltrials.gov) - P3; N=307; Completed; Sponsor: Daré Bioscience, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion • Vaginitis

DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE) (clinicaltrials.gov) - P3; N=240; Active, not recruiting; Sponsor: Daré Bioscience, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Vaginitis

DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE) (clinicaltrials.gov) - P3; N=240; Recruiting; Sponsor: Daré Bioscience, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open